|
1. BIOLOGIE
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
|
3.4 CHIMIOPRÉVENTION
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.4 PHARMA - LILLY
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA,...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
European Commission expands use for Janssen’s Erleada [Pharma Times]
|
|
|
|
|
|
Janssen has announced that the European Commission (EC) has granted marketing authorisation for the expanded use of Erleada (apalutamide), to now include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
6.10 POLITIQUES
|
|
|